Valneva to Further Consolidate its Operations in France 

26 Nov 2025 17:30 CET

• French operations to be concentrated at its Lyon site 
  
• Final consolidation of R&D in Vienna 

Saint-Herblain (France), November 26, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) today announced a strategic initiative to optimize its organizational footprint in France  as part of the Company’s ongoing efforts to increase operational effectiveness and position Valneva for long-term success. 

The Company plans to concentrate its French operations at its Lyon location, closing the site in Nantes, which currently includes operational as well as certain pre-clinical R&D activities. This consolidation will streamline operations and improve efficiency in France, while also centralizing all R&D activities at the Company’s site in Vienna. 

Valneva plans to relocate its registered office back to Lyon, where it was originally established, and maintain its listing on Euronext Paris. The city of Lyon in France is internationally recognized as a leading vaccine hub, home to major players such as Sanofi Pasteur and the Mérieux group, making it an ideal location for Valneva to concentrate its French operations. 

Valneva is committed to supporting employees throughout this transition and providing assistance to ensure a smooth process for all impacted team members. 

About Valneva SE 
We are a specialty vaccine company that develops, manufactures, and commercializes prophylactic vaccines for infectious diseases addressing unmet medical needs. We take a highly specialized and targeted approach, applying our deep expertise across multiple vaccine modalities, focused on providing either first-, best- or only-in-class vaccine solutions. 
We have a strong track record, having advanced multiple vaccines from early R&D to approvals, and currently market three proprietary travel vaccines. Revenues from our growing commercial business help fuel the continued advancement of our vaccine pipeline. This includes the only Lyme disease vaccine candidate in advanced clinical development, which is partnered with Pfizer, the world’s most clinically advanced Shigella vaccine candidate, as well as vaccine candidates against other global public health threats. More information is available at www.valneva.com. 
 

Valneva Forward-Looking Statements 
This press release contains certain forward-looking statements relating to the business of Valneva, including with respect to the progress, timing, results and completion of research, development and clinical trials for product candidates, to regulatory approval of product candidates and review of existing products, and financial guidance including projected product sales, total revenue and total R&D investments. In addition, even if the actual results or development of Valneva are consistent with the forward-looking statements contained in this press release, those results or developments of Valneva may not be sustained in the future. In some cases, you can identify forward-looking statements by words such as “could,” “should,” “may,” “expects,” “anticipates,” “believes,” “intends,” “estimates,” “aims,” “targets,” or similar words. These forward-looking statements are based largely on the current expectations of Valneva as of the date of this press release and are subject to a number of known and unknown risks and uncertainties and other factors that may cause actual results, performance or achievements to be materially different from any future results, performance or achievement expressed or implied by these forward-looking statements. In particular, the expectations of Valneva could be affected by, among other things, uncertainties and delays involved in the development and manufacture of vaccines, unexpected clinical trial results, unexpected regulatory actions or delays, competition in general, currency fluctuations, the impact of the global and European credit crisis, and the ability to obtain or maintain patent or other proprietary intellectual property protection. Success in preclinical studies or earlier clinical trials may not be indicative of results in future clinical trials. In light of these risks and uncertainties, there can be no assurance that the forward-looking statements made in this press release will in fact be realized. Valneva is providing this information as of the date of this press release and disclaims any intention or obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise. 

Attachment

• 2025_11_26_Operational Update_PR_EN_FINAL